What the man in the street thinks about human enhancement
By Michael Cook,
BioEdge
| 05. 07. 2016
[citing CGS consultant Pete Shanks]
Untitled Document
What does the American public think about human germline enhancement? A survey of 17 polls taken over the 30 years published in the New England Journal of Medicine suggests that Americans support gene therapy for patients with serious diseases, but they oppose it in embryos or germ cells. The authors conclude: “Of course, public opinion could change over time as discussions of these issues continue to evolve and as more is learned about the implications and safety of gene-editing technologies.”
However, Pete Shanks, at the Center for Genetics and Society, in California, reaches a different conclusion from much the same information. The latest polls show that more than 80% of people surveyed thought that babies should not be genetically modified for increased intelligence or sporting ability. “These are, or should be, devastating numbers to anyone who thinks that the public supports human heritable genetic modification,” he concludes.
Image via Pixabay
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Ava Kofman, The New Yorker | 02.09.2026
1. The Surrogates
In the delicate jargon of the fertility industry, a woman who carries a child for someone else is said to be going on a “journey.” Kayla Elliott began hers in February, 2024, not long after she posted...
By Alex Polyakov, The Conversation | 02.09.2026
Prospective parents are being marketed genetic tests that claim to predict which IVF embryo will grow into the tallest, smartest or healthiest child.
But these tests cannot deliver what they promise. The benefits are likely minimal, while the risks to...
By Pei-Chieh Hsu, Taiwan Insight | 02.02.2026